Skip to main content
. 2010 Jun 1;2:143–156. doi: 10.2147/cmar.s5398

Figure 5.

Figure 5

Design of erlotinib maintenance phase III trials in advanced NSCLC treatment (SATURN73 and ATLAS74).

Abbreviations: NSCLC, non-small cell lung cancer; non-PD, complete responses, partial responses, stable disease; PD, progressive disease; PFS, progression-free survival.